All treatments
Treatment
Vabysmo 120 mg/mL solution for injection clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase III and phase IV (Integrated)
Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)
This study compares two treatments, Vabysmo and Eylea, for a serious eye condition called 'wet' age-related macular degeneration (AMD). The aim is to see which treatment can keep the eye healthy and vision stable for longer, with fewer injections.
For: Neovascular age-related macular degenerationAustria - Ongoing, recruitingTherapeutic use (Phase IV)
Two initial faricimab loading doses in treatment-naive neovascular AMD
This study looks at a new way to treat wet age-related macular degeneration (AMD) using a medicine called Vabysmo. Doctors want to see if giving two starting doses helps control the disease quickly, checking patients after 8 weeks to see how well it's working.
For: Neovascular age-related macular degenerationAustria